|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's Range||84.13 - 87.15|
|52 Week Range||69.27 - 92.74|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||18.44|
|Forward Dividend & Yield||4.68 (5.47%)|
|Ex-Dividend Date||Dec 17, 2019|
|1y Target Est||N/A|
Alongside fashionable brand names like Mercedes-Benz and Chopard on the red carpet backdrop at Germany's Bambi Awards last year: IQOS. That's Philips Morris' alternative cigarette that heats up but doesn't burn ground-up tobacco. A study by tobacco researchers at Stanford University says such promotions are part of the company's "normalization" strategy. That strategy, it says, aims to scrub the company's image as a maker of cigarettes that cause cancer ... and market its smoking alternatives as youthful, upscale lifestyle products. The Stanford professor who led the study says Philip Morris is trying to resurrect the glory era of smoking by associating IQOS with a glamorous and stylish lifestyle. Last year, a Reuters investigation found that Philip Morris had used young online personalities to promote IQOS. That prompted the company to admit that it had violated its own policy that prohibits it from using youth-oriented celebrities or models who are or appear to be under 25. But the Stanford study says IQOS marketing continues to substantially stray from those corporate standards by using youth-oriented social media channels, trendy pop music festivals and celebrity influencers. In Israel, the brand was present at a Tel Aviv University student music festival last year where the minimum age for admission was 16. Philip Morris partners with Altria to sell IQOS in about 50 countries including the U.S. They've pledged to regulators that they would market it only to adult smokers. But in other countries, the Stanford study says the company uses what it calls "coaches" and "ambassadors" to market IQOS. In Romania and Russia, THAT MEANS RECRUITING ATTRACTIVE WOMEN AS YOUNG AS 19 TO MARKET THE DEVICE, ACCORDING TO JOB LISTINGS REVIEWED BY REUTERS. Philip Morris did not respond to questions about its business relationships with the establishments that promote the device and display its branding.
(Bloomberg Opinion) -- A quarter century ago, a man named Steve Parrish was the ugly voice of the tobacco industry. The tobacco wars were raging: States were suing the cigarette companies, whistle-blowers were leaking damning documents to the media and David Kessler, the commissioner of the Food and Drug Administration, was trying to regulate tobacco products.Parrish was a senior executive at Altria at the time, and his job was to strike back. He would go on television and hurl insults at Kessler. He would insist that cigarettes weren’t addictive. He would denounce the mounting lawsuits in strident language.Eventually, though, Parrish realized that Big Tobacco had no choice but to negotiate with its opponents. And once he sat down with the other side, a funny thing happened. His anger dissipated when he realized that Big Tobacco’s critics were reasonable people with legitimate concerns — and that Altria, stuck in its bunker for so long, had been wrong to dismiss them. “All we knew was our own rhetoric,” he told me years later. Ultimately, those negotiations led the tobacco companies to agree to pay the states $246 billion and accept tighter restrictions on cigarette marketing.I bring this up because of something that took place last week. On Wednesday morning, Vital Strategies, a leading global public health organization, sponsored a talk titled “Hope Meets Reality: E-Cigarettes, a Public Health Harm or Harm Reduction?” The event was a one-sided assault on e-cigarettes.One speaker was Matthew Myers, the president of the Campaign for Tobacco-Free Kids. Myers has been a critic of e-cigarettes from the start — but he’s been in overdrive ever since Juul became the e-cigarette of choice for teenagers. Its manufacturer, Juul Labs Inc., faces a host of legal woes, including a joint investigation by 39 attorneys general announced on Tuesday. (Both Vital Strategies and the Campaign for Tobacco-Free Kids are supported financially by Bloomberg Philanthropies.)After his talk, Myers was joined on stage by another e-cigarette critic, Joanna Cohen, the director of the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health. The two of them took turns bashing e-cigarettes. Myers complained about “the few zealous people” who continued to argue that e-cigarettes could save lives; Cohen claimed that “there was some evidence of nicotine’s effect on the cardiovascular system.” And so on.Among those who had registered to attend the talk was Moira Gilchrist, the vice president for scientific and public communications at Philip Morris International. That’s right: She’s part of Big Tobacco. Gilchrist is in charge of the company’s harm-reduction efforts. The scientists she leads devise nicotine products that won’t kill consumers the way cigarettes do.Virtually everyone in the public health community is skeptical that Philip Morris is serious about transitioning the company to products that don’t rely on deadly combustible tobacco. But Gilchrist is a true believer. She joined the company a dozen years ago after working at a leading cancer charity in the U.K., she told me the other day. “This is not something we are doing for show,” she said. “This is our commercial future.”A few days before the Vital Strategies talk, Gilchrist received a note from the group disinviting her. “In accordance with our non-engagement policy, tobacco industry representatives will not be granted access,” it read. In an accompanying statement, Vital Strategies elaborated: Let us be clear: There is a fundamental and irreconcilable conflict of interest between public health and the tobacco industry. And as an organization whose mission is to ensure everyone is protected by a strong public health system, we at Vital Strategies align ourselves with the World Health Organization, governments around the world, and the global health community in upholding a firm non-engagement policy with the tobacco industry.As it turns out, the talk was streamed, and Gilchrist was able to watch it. When we spoke the next day, she told me that there were things that Myers and Cohen had said that she would have liked to challenge if she had been allowed in the room.For instance, the case that nicotine harms the cardiovascular system has been made most prominently by Stanley Glantz, an anti-tobacco zealot who is a professor at the University of California, San Francisco. One widely quoted Glantz study published last year purported to show that e-cigarettes doubled the risk of heart attacks. But last week, the Journal of the American Heart Association retracted that study because its data was “unreliable.”As for Myers, one of the key points he made in his talk was that there was no evidence that smokeless nicotine devices were causing large numbers of adults to quit smoking but there was lots of evidence that they were hooking teenagers. Of course, part of the reason adult smokers aren’t racing to take up e-cigarettes is that the public health community has heaped such abuse on them that many adults don’t realize they are safer than cigarettes.Philip Morris doesn’t make an e-cigarette like Juul. Its product, called IQOS, delivers nicotine by heating tobacco rather than burning it. And as Gilchrist pointed out when we spoke, there is plenty of evidence that it is moving smokers away from cigarettes. In Japan, IQOS has nearly 18% of the market — not the smokeless market, but the tobacco market, including cigarettes. (“We have seen the most remarkable drop in cigarette sales,” she said.) In Russia it has 5% of the market. In Portugal 7.2%.Last spring, the FDA approved the device for sale in the U.S., ruling that it is “appropriate for the protection of public health” because it contains fewer toxins than cigarettes. Philip Morris has now submitted data to the agency as it seeks a designation that would allow it to market IQOS as less harmful than cigarettes — something e-cigarettes are not allowed to do. That would be a tremendously big deal.Gilchrist told me that there were many things public health advocates believe that Philip Morris also believes: that e-cigarettes should be kept away from youths, for instance, and that the products should be heavily regulated, based on sound science. But, she added, “what I see is that the public health organizations are using youth use as a reason to deprive 40 million U.S. smokers from having access to these products.” She added:This is the future of this company. We have the product, the science, and the will to make it work. For us, there is one path forward and it is smoke-free products. The question is whether public health wants to make it more difficult for us or less difficult.I understand why the public health community doesn’t want to legitimize the tobacco companies by meeting with them; they did a lot of shameful things in the past, and they still sell a product that kills about half its users. The memory of those old sins makes public health officials skeptical that tobacco executives like Gilchrist are sincere when they say they want a cigarette-free future.But the only way we’re going to solve the e-cigarette conundrum — namely, how do we keep the products away from youths while urging adult smokers to make the switch? — is if the two sides sit down and start talking. I think the public health officials would see — just as Parrish saw two decades ago — that those on the other side genuinely want to find a solution. At that point, the two sides could fairly easily come up with proposals that would work for everyone. The refusal to engage with the tobacco companies is actually harming public health.As I’ve noted before, one of the people who negotiated with Parrish all those years ago was Myers. It took a lot of guts; when his allies in the public health community discovered that he was involved in the tobacco settlement talks, he was roundly denounced. But he stuck with it and helped change the cigarette landscape for the better. If only he were willing to do it again, he could hasten the end of cigarettes.(Adds announcement of an investigation into Juul Labs Inc. in the fifth paragraph. )To contact the author of this story: Joe Nocera at firstname.lastname@example.orgTo contact the editor responsible for this story: Daniel Niemi at email@example.comThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Joe Nocera is a Bloomberg Opinion columnist covering business. He has written business columns for Esquire, GQ and the New York Times, and is the former editorial director of Fortune. His latest project is the Bloomberg-Wondery podcast "The Shrink Next Door."For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Alongside the likes of Mercedes-Benz and Swiss watchmaker Chopard was a newer name: IQOS, a "reduced risk" heated-tobacco device sold by cigarette maker Philip Morris International Inc. Across Europe, Asia and South America, the tobacco firm has affixed the IQOS brand to music festivals and art exhibits. Throughout Europe, it has partnered with "IQOS friendly" bars and restaurants - closed to cigarettes but open to IQOS.
Philip Morris, the New York tobacco giant, affirmed its 2020 earnings guidance of $5.50 a share. That figure was short of analysts' consensus expectation of $5.58.
Philip Morris International Inc. shares slid 3.6% in premarket trade Wednesday before reversing those losses, after the Marlboro cigarette maker said it still expects 2020 per-share earnings of $5.50, below the $5.59 FactSet consensus. The company reiterated its guidance in a statement published ahead of a presentation later in the day at the Consumer Analyst Group of New York (CAGNY) Conference in Boca Raton, Florida. The guidance includes a 4 cents per share impact from currency movements. The company is assuming total international industry volumes, excluding China and the U.S., will decline 3% to 4%, partly due to the impact of an above-inflation excise tax increase in Indonesia, and the further shift to the cigarillo category in Japan. Those items are expected to account for about 100 basis points of the decline. The company is expecting total cigarette and heated tobacco unit shipment volume of 2.5% to 3.5%. Shares have gained 4.9% in the last 12 months, while the S&P 500 has gained 21%.
Investors in Philip Morris International Inc. (NYSE:PM) had a good week, as its shares rose 6.2% to close at US$88.75...
U.S. stocks gained for a fourth straight session on Thursday and Wall Street's main indexes hit record highs as concerns eased over the economic fallout from the coronavirus outbreak in China. China said it would halve additional tariffs levied against some U.S. goods, seen by analysts as a move to boost confidence after the fast-spreading coronavirus disrupted businesses and sparked broad market volatility. The Dow Jones Industrial Average rose 88.92 points, or 0.3%, to 29,379.77, the S&P 500 gained 11.09 points, or 0.33%, to 3,345.78 and the Nasdaq Composite added 63.47 points, or 0.67%, to 9,572.15.
The world's largest cigarette makers, British American Tobacco Plc and Philip Morris International, will have until early March to defend themselves in a lawsuit in Brazil over compensation for tobacco-related diseases. Since last year, the companies have refused to receive subpoenas delivered to their local subsidiaries in the lawsuit brought the Brazilian solicitor general's office. Souza Cruz Ltda, Philip Morris Brasil Industria e Comercio Ltda and Philip Morris Brasil SA, which produce 90% of the cigarettes sold in Brazil, maintained they were subsidiaries only and notifications had to be sent directly to their parent companies' headquarters in Britain and the United States.
The cigarette maker’s earnings per share were a penny higher than expected. Cigarette sales volume dropped 8% in the fourth quarter but volume soared for so-called heated tobacco products.
The S&P 500 and Dow Jones Industrials indexes eased from their record highs on Thursday, as investors took a breather after a stellar run this week on waning worries about the economic damage from the coronavirus epidemic. Both indexes scaled new levels at the open as China said it would halve extra tariffs on some U.S. goods following hefty stimulus to support an economy hit by shutdowns and travel restrictions due to the virus outbreak.
(Bloomberg) -- Philip Morris International Inc., the international seller of Marlboros, forecast that profit this year will be lifted by sales of tobacco sticks for IQOS devices.Earnings per share should rise at least 19% to $5.50 this year, based on current exchange rates, the company forecast. That’s short of the $5.61 analysts have been expecting.Key InsightsThe company launched its latest IQOS 3 Duo in Japan in September. IQOS’s 41% growth in the fourth quarter suggests it’s holding its own against heightened competition in the market for smoking alternatives.Philip Morris has said that as people smoke fewer combustible cigarettes, it plans not only to switch them to next-generation devices like IQOS, but also maintain a strong share of the cigarette market. Its total international cigarette market share was 26.9%, down 0.3% points.The performance contrasts with that of smaller rivals such as Imperial Brands Plc, the maker of Kool cigarettes, which has warned of declining sales from its smoking alternatives. Philip Morris sold 60 billion heat sticks last year and said it’s on track to reach its goal to ship as many as 100 billion in 2021.Market ReactionPhilip Morris has gained 11% in the past year.For the company statement, click here.To contact the reporter on this story: Tiffany Kary in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Sally Bakewell at email@example.com, Thomas MulierFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Philip Morris International Inc. said Thursday it had net income of $1.616 billion, or $1.04 a share, in the fourth quarter, down from $1.910 billion, or $1.23 a share, in the year-earlier period. The maker of Marlboro cigarettes said adjusted per-share earnings came to $1.22, ahead of the $1.21 FactSet consensus. Revenue rose 2.9% to $7.713 billion from $7.499 billion, also ahead of the $7.661 billion FactSet consensus. "Although we anticipate a few temporary headwinds, notably in Indonesia, we enter 2020 with favorable momentum, and expect to deliver like-for-like currency-neutral net revenue and adjusted diluted EPS growth this year consistent with our 2019 to 2021 compound annual growth targets of at least 5% and 8%, as well as further margin expansion," Chief Executive Andre Calantzopoulos said in a statement. The company is now expecting full-year adjusted EPS of $5.50, below the $5.60 FactSet consensus. Shares were slightly higher premarket, but have gained 11% in the last 12 months, while the S&P 500 has gained 22%.
Investing.com - Philip Morris (NYSE:PM) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Philip Morris Intl (NYSE: PM ) will be releasing its next round of earnings this Thursday, February 6. For all of the relevant information, here is your guide for the Q4 earnings announcement. Earnings ...